(Q34994453)

5 August 2017

1 reference

title

Essential thrombocythemia: past and present (English)

1 reference

5 August 2017

Fabrizio Fabris

1

1 reference

5 August 2017

Maria Luigia Randi

series ordinal

2

1 reference

5 August 2017

publication date

28 July 2009

1 reference

Internal and emergency medicine

5 August 2017

published in

1 reference

5 August 2017

volume

4

1 reference

5 August 2017

issue

5

1 reference

5 August 2017

page(s)

381-388

1 reference

Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders

5 August 2017

cites work

1 reference

Crossref

https://api.crossref.org/works/10.1007%2FS11739-009-0284-X

The World Health Organization (WHO) classification of the myeloid neoplasms

21 January 2018

1 reference

12 December 2020

X-inactivation-based clonality analysis and quantitative JAK2V617F assessment reveal a strong association between clonality and JAK2V617F in PV but not ET/MMM, and identifies a subset of JAK2V617F-negative ET and MMM patients with clonal hematopoies

1 reference

12 December 2020

Life expectancy and prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders.

1 reference

12 December 2020

Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta

1 reference

12 December 2020

Hydroxyurea for patients with essential thrombocythemia and a high risk of thrombosis

1 reference

12 December 2020

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis

1 reference

12 December 2020

Polymorphonuclear leukocyte activation and hemostasis in patients with essential thrombocythemia and polycythemia vera

1 reference

12 December 2020

Response criteria for essential thrombocythemia and polycythemia vera: result of a European LeukemiaNet consensus conference.

1 reference

12 December 2020

Primary hemorrhagic thrombocythemia

1 reference

12 December 2020

Definition of subtypes of essential thrombocythaemia and relation to polycythaemia vera based on JAK2 V617F mutation status: a prospective study.

1 reference

12 December 2020

Altered gene expression in myeloproliferative disorders correlates with activation of signaling by the V617F mutation of Jak2.

1 reference

12 December 2020

Essential thrombocythemia: an interim report from the Polycythemia Vera Study Group

1 reference

12 December 2020

Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia

1 reference

12 December 2020

The genetic basis of myeloproliferative disorders

1 reference

12 December 2020

Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel

1 reference

12 December 2020

Acquired von Willebrand syndrome: an important bleeding complication to be considered in patients with lymphoproliferative and myeloproliferative disorders

1 reference

12 December 2020

A unified definition of clinical resistance/intolerance to hydroxyurea in essential thrombocythemia: results of a consensus process by an international working group.

1 reference

12 December 2020

Some speculations on the myeloproliferative syndromes.

1 reference

12 December 2020

Bone marrow pathology in essential thrombocythemia: interobserver reliability and utility for identifying disease subtypes

1 reference

12 December 2020

Incidence and risk factors for thrombotic complications in a historical cohort of 100 patients with essential thrombocythemia

1 reference

12 December 2020

Efficacy and safety of low-dose aspirin in polycythemia vera

1 reference

12 December 2020

Thrombocythemia; report of three cases and review of literature

1 reference

12 December 2020

Incidence of essential thrombocythaemia in children

1 reference

12 December 2020

Increased risk of pregnancy complications in patients with essential thrombocythemia carrying the JAK2 (617V>F) mutation

1 reference

12 December 2020

Chronic myeloproliferative disorders with thrombocythemia: a comparative study of two classification systems (PVSG, WHO) on 839 patients

1 reference

12 December 2020

Toxicity and side effects of hydroxyurea used for primary thrombocythemia

1 reference

12 December 2020

Identification of an acquired JAK2 mutation in polycythemia vera

1 reference

12 December 2020

JAK2 mutation in essential thrombocythaemia: clinical associations and long-term prognostic relevance

1 reference

12 December 2020

Second malignancies in patients with essential thrombocythaemia treated with busulphan and hydroxyurea: long-term follow-up of a randomized clinical trial

1 reference

12 December 2020

Thrombocytosis and leukocytosis interaction in vascular complications of essential thrombocythemia.

1 reference

12 December 2020

Evidence that essential thrombocythemia is a clonal disorder with origin in a multipotent stem cell

1 reference

12 December 2020

Hemorrhagic thrombocythemia: a critical review.

1 reference

12 December 2020

Clinical profile of homozygous JAK2 617V>F mutation in patients with polycythemia vera or essential thrombocythemia

1 reference

12 December 2020

Essential thrombocythaemia: challenges and evidence-based management

1 reference

12 December 2020

Essential thrombocythemia in children

1 reference

12 December 2020

Epidemiology of the myeloproliferative disorders polycythemia vera and essential thrombocythemia

1 reference

12 December 2020

The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases

1 reference

12 December 2020

Features of essential thrombocythaemia in childhood: a study of five children

1 reference

12 December 2020

Thrombosis and haemorrhage in polycythaemia vera and essential thrombocythaemia

1 reference

12 December 2020

A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera

1 reference

12 December 2020

Long-term use of anagrelide in young patients with essential thrombocythemia

1 reference

12 December 2020

Leukocytosis is a risk factor for thrombosis in essential thrombocythemia: interaction with treatment, standard risk factors, and Jak2 mutation status

1 reference

12 December 2020

Aspirin in essential thrombocythemia: status quo and quo vadis

1 reference

12 December 2020

Hydroxyurea compared with anagrelide in high-risk essential thrombocythemia

1 reference

12 December 2020

Pipobroman is safe and effective treatment for patients with essential thrombocythaemia at high risk of thrombosis.

1 reference

12 December 2020

Essential thrombocythaemia in children: is a treatment needed?

1 reference

12 December 2020

Normal thrombopoietin and its receptor (c-mpl) genes in children with essential thrombocythemia.

1 reference

12 December 2020

Pediatric patients with essential thrombocythemia are mostly polyclonal and V617FJAK2 negative.

1 reference

12 December 2020

Anagrelide for control of thrombocythemia in polycythemia and other myeloproliferative disorders

1 reference

12 December 2020

Practice guidelines for the therapy of essential thrombocythemia. A statement from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation.

1 reference

12 December 2020

10.1007/S11739-009-0284-X

Identifiers

DOI

1 reference

5 August 2017

1 reference